Catherine Sabatos-Peyton

3.2k total citations · 3 hit papers
23 papers, 2.1k citations indexed

About

Catherine Sabatos-Peyton is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Catherine Sabatos-Peyton has authored 23 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 13 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Catherine Sabatos-Peyton's work include Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (6 papers) and CAR-T cell therapy research (5 papers). Catherine Sabatos-Peyton is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (6 papers) and CAR-T cell therapy research (5 papers). Catherine Sabatos-Peyton collaborates with scholars based in United States, Switzerland and Canada. Catherine Sabatos-Peyton's co-authors include Ana C. Anderson, Nandini Acharya, David C. Wraith, Johan Verhagen, Glenn Dranoff, Lilli Petruzzelli, Sonia Quaratino, Becker Hewes, Scott B. Cameron and Philip J. Gotwals and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Catherine Sabatos-Peyton

23 papers receiving 2.1k citations

Hit Papers

Prospects for combining t... 2017 2026 2020 2023 2017 2020 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prospects for combining targeted and conventional cancer therapy with immunotherapy
    2017 766 citations Philip J. Gotwals, Scott B. Cameron et al. Nature reviews. Cancer profile →
  2. Tim-3 finds its place in the cancer immunotherapy landscape
    2020 301 citations Nandini Acharya, Catherine Sabatos-Peyton et al. Journal for ImmunoTherapy of Cancer profile →
  3. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
    2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Catherine Sabatos-Peyton 1.2k 1.1k 475 233 222 23 2.1k
M. Ángela Aznar 1.5k 1.3× 1.5k 1.3× 715 1.5× 185 0.8× 295 1.3× 23 2.5k
Colm R. Duffy 1.1k 0.9× 1.6k 1.4× 514 1.1× 394 1.7× 173 0.8× 11 2.3k
Danny N. Khalil 637 0.5× 950 0.8× 410 0.9× 274 1.2× 269 1.2× 40 1.6k
Sydney Gordon 1.7k 1.4× 1.4k 1.2× 740 1.6× 293 1.3× 231 1.0× 10 2.8k
Kyohei Nakamura 986 0.8× 793 0.7× 537 1.1× 180 0.8× 148 0.7× 37 1.9k
Vikram R. Juneja 1.4k 1.2× 1.4k 1.2× 947 2.0× 271 1.2× 177 0.8× 19 2.6k
Ilaria Grazia Zizzari 782 0.6× 1.1k 0.9× 663 1.4× 315 1.4× 162 0.7× 61 1.9k
Lydia Koenig 939 0.8× 1.2k 1.0× 456 1.0× 230 1.0× 185 0.8× 14 1.9k
Whitney L. Gladney 1.2k 1.0× 1.8k 1.6× 584 1.2× 250 1.1× 415 1.9× 24 2.4k
Helena Escuin-Ordinas 1.0k 0.8× 1.4k 1.2× 644 1.4× 273 1.2× 130 0.6× 19 2.1k

Countries citing papers authored by Catherine Sabatos-Peyton

Since Specialization
Citations

This map shows the geographic impact of Catherine Sabatos-Peyton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Sabatos-Peyton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Sabatos-Peyton more than expected).

Fields of papers citing papers by Catherine Sabatos-Peyton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Sabatos-Peyton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Sabatos-Peyton. The network helps show where Catherine Sabatos-Peyton may publish in the future.

Co-authorship network of co-authors of Catherine Sabatos-Peyton

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Sabatos-Peyton. A scholar is included among the top collaborators of Catherine Sabatos-Peyton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Sabatos-Peyton. Catherine Sabatos-Peyton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Chia‐Chi, Giuseppe Curigliano, Armando Santoro, et al.. (2024). Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study. BMJ Open. 14(8). e079132–e079132. 8 indexed citations
2.
Corse, Emily, Krista Goodman, Guosen Ye, et al.. (2024). Abstract 5574: Degradation of PIP4K2C by novel bivalent functional degrader LRK-A induces tumor regression in CRC. Cancer Research. 84(6_Supplement). 5574–5574. 1 indexed citations
3.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629. 257 indexed citations breakdown →
4.
Huuhtanen, Jani, Oscar Brück, Karita Peltonen, et al.. (2021). Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS. Blood. 138(Supplement 1). 801–801. 1 indexed citations
5.
Acharya, Nandini, Catherine Sabatos-Peyton, & Ana C. Anderson. (2020). Tim-3 finds its place in the cancer immunotherapy landscape. Journal for ImmunoTherapy of Cancer. 8(1). e000911–e000911. 301 indexed citations breakdown →
6.
Singh, Reshma, Rohan Diwanji, Pushpa Jayaraman, et al.. (2020). Abstract A76: Anti IL-1b as a cancer immunotherapy. Cancer Immunology Research. 8(4_Supplement). A76–A76. 1 indexed citations
7.
Jayaraman, Pushpa, Vanessa Rodrik-Outmezguine, John M. Millholland, et al.. (2020). Abstract 5640: Targeting tumor-promoting inflammation (TPI) via the IL-1βpathway for cancer immunotherapy. Cancer Research. 80(16_Supplement). 5640–5640. 3 indexed citations
8.
Jayaraman, Pushpa, John M. Millholland, Neil A. O’Brien, et al.. (2019). Abstract C103: Targeting IL-1β pathway for cancer immunotherapy. Molecular Cancer Therapeutics. 18(12_Supplement). C103–C103. 3 indexed citations
9.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2019). Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Research. 79(13_Supplement). CT183–CT183. 32 indexed citations
10.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2019). Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Clinical Trials. CT183–CT183. 2 indexed citations
11.
Hong, David S., Patrick Schöffski, Aitana Calvo, et al.. (2018). Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 36(15_suppl). 3012–3012. 61 indexed citations
12.
Britton, Graham J., Rachel Ambler, Elaine V. Hill, et al.. (2017). PKCθ links proximal T cell and Notch signaling through localized regulation of the actin cytoskeleton. eLife. 6. 15 indexed citations
13.
Gotwals, Philip J., Scott B. Cameron, Daniela Cipolletta, et al.. (2017). Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature reviews. Cancer. 17(5). 286–301. 766 indexed citations breakdown →
14.
Jing, Weiqing, Jill A. Gershan, James J. Weber, et al.. (2015). Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. Journal for ImmunoTherapy of Cancer. 3(1). 2–2. 98 indexed citations
15.
Burton, Bronwen R., Graham J. Britton, Hai Fang, et al.. (2014). Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nature Communications. 5(1). 4741–4741. 141 indexed citations
16.
Verhagen, Johan, Raphaël Genolet, Graham J. Britton, et al.. (2012). CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proceedings of the National Academy of Sciences. 110(3). E221–30. 41 indexed citations
17.
Mazza, Graziella, Catherine Sabatos-Peyton, Rachel Protheroe, et al.. (2010). Isolation and characterization of human interleukin-10–secreting T cells from peripheral blood. Human Immunology. 71(3). 225–234. 9 indexed citations
18.
Sabatos-Peyton, Catherine, Johan Verhagen, & David C. Wraith. (2010). Antigen-specific immunotherapy of autoimmune and allergic diseases. Current Opinion in Immunology. 22(5). 609–615. 103 indexed citations
19.
Anderson, Ana C., Graham M. Lord, Valérie Dardalhon, et al.. (2010). T‐bet, a Th1 transcription factor regulates the expression of Tim‐3. European Journal of Immunology. 40(3). 859–866. 92 indexed citations
20.
Gabryšová, Leona, Kirsty Nicolson, Heather B. Streeter, et al.. (2009). Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10–secreting Th1 cells. The Journal of Experimental Medicine. 206(8). 1755–1767. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Ángela Aznar Breakdown of academic impact, for papers by Colm R. Duffy Breakdown of academic impact, for papers by Danny N. Khalil Breakdown of academic impact, for papers by Sydney Gordon Breakdown of academic impact, for papers by Kyohei Nakamura Breakdown of academic impact, for papers by Vikram R. Juneja Breakdown of academic impact, for papers by Ilaria Grazia Zizzari Breakdown of academic impact, for papers by Lydia Koenig Breakdown of academic impact, for papers by Whitney L. Gladney Breakdown of academic impact, for papers by Helena Escuin-Ordinas
Rankless by CCL
2026